Outlook Therapeutics, Inc.

Kevin Lundquist, Chief Financial Officer of Outlook Therapeutics, Inc., filed an initial Form 3 statement of beneficial ownership upon becoming a Section 16 reporting person. The filing reports no securities of the issuer currently owned. This is a standard initial disclosure required for newly appointed Section 16 officers.

Outlook Therapeutics (OTLK) disclosed that CFO Lawrence Kenyon will depart the company on September 1, 2026, and that Kevin Lundquist has been appointed as the new Chief Financial Officer, also effective September 1. Lundquist previously served as CFO at CapsoVision, bringing relevant med-tech financial leadership experience to Outlook. No cause for Kenyon's departure was disclosed, and there is no indication of disagreement with management. The transition is effective immediately with no interim gap period.

GMS Ventures & Investments (Cayman Islands) and affiliated Ghiath M. Sukhtian (Jordan) filed Amendment No. 7 to their Schedule 13D on Outlook Therapeutics, with an event date of August 12, 2026. GMS Ventures beneficially owns 42,631,142 shares including warrants to purchase 18,013,822 shares, representing 16.4% based on the 242,672,554 shares outstanding after the August 2026 public offering. At 16.4%, GMS Ventures is a significant check on management following the dilutive equity raise.

Outlook Therapeutics priced a public offering of 55,555,556 shares plus accompanying warrants to purchase 55,555,556 shares at a combined price of $0.99 per unit (~$0.98/share + $0.01/warrant), raising gross proceeds of approximately $55 million ($51.7 million net). Warrants carry a $1.10 exercise price and a five-year term; underwriters have an option for an additional 8,333,333 shares/warrants over 30 days. The last trade was $1.10 on August 12, 2026. Highly dilutive offering — 55.6M new shares materially expands the share count while raising critical capital at a slight discount to market.

Outlook Therapeutics (OTLK) filed a preliminary 424B5 prospectus supplement on August 13, 2026 for an equity offering of an unspecified number of shares and warrants; the last reported sale price was $1.13 per share, indicating this is a dilutive offering at a very low stock price. Dollar amounts and share counts were not yet determined in this preliminary filing. Outlook Therapeutics develops ophthalmic drug treatments; its bevacizumab eye drop formulation targets wet AMD. A sub-$2 offering price signals financial distress and near-term cash needs.

Outlook Therapeutics, Inc. filed an 8-K on July 21, 2026 under Item 5.02, disclosing a departure or appointment of a director or officer. The body excerpt contains only the standard cover page. This is a routine leadership change at the ophthalmic biotech; the executive identity and role are in the attached exhibit. (A separate 8.01 filing was also made three days later — Job 32.)

Outlook Therapeutics filed an S-3 shelf registration to register securities for future capital raises and is calling a special shareholder meeting to vote on increasing authorized shares from 260 million to 600 million and approving warrant exercises. The expanded share authorization is needed to support additional capital raises for the ophthalmology biopharmaceutical company.

Outlook Therapeutics held a special shareholder meeting to vote on proposals to increase authorized shares from 260 million to 600 million and approve warrant exercises. The vote on expanded share authorization provides the capital structure flexibility needed to support potential equity raises tied to the company's S-3 shelf registration.